Astaxanthin: a Potential Mitochondrial-Targeted Antioxidant Treatment in Diseases and with Aging by Sztretye, Mónika et al.
Review Article
Astaxanthin: A Potential Mitochondrial-Targeted Antioxidant
Treatment in Diseases and with Aging
Mónika Sztretye,1 Beatrix Dienes ,1 Mónika Gönczi ,1 Tamás Czirják,1
László Csernoch ,1 László Dux,2 Péter Szentesi ,1 and Anikó Keller-Pintér 2
1Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen H-4002, Hungary
2Department of Biochemistry, Faculty of Medicine, University of Szeged, Szeged H-6720, Hungary
Correspondence should be addressed to Péter Szentesi; szentesi.peter@med.unideb.hu
and Anikó Keller-Pintér; keller.aniko@med.u-szeged.hu
Received 19 April 2019; Accepted 30 August 2019; Published 11 November 2019
Guest Editor: Konstantin Lyamzaev
Copyright © 2019Mónika Sztretye et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Oxidative stress is characterized by an imbalance between prooxidant and antioxidant species, leading to macromolecular damage
and disruption of redox signaling and cellular control. It is a hallmark of various diseases including metabolic syndrome, chronic
fatigue syndrome, neurodegenerative, cardiovascular, inﬂammatory, and age-related diseases. Several mitochondrial defects have
been considered to contribute to the development of oxidative stress and known as the major mediators of the aging process
and subsequent age-associated diseases. Thus, mitochondrial-targeted antioxidants should prevent or slow down these processes
and prolong longevity. This is the reason why antioxidant treatments are extensively studied and newer and newer compounds
with such an eﬀect appear. Astaxanthin, a xanthophyll carotenoid, is the most abundant carotenoid in marine organisms and is
one of the most powerful natural compounds with remarkable antioxidant activity. Here, we summarize its antioxidant targets,
eﬀects, and beneﬁts in diseases and with aging.
1. Introduction
The extended human life span over the past decades is
causing the world’s population to age. Accordingly, the prev-
alence of chronic diseases, cognitive decline, and disability
increases in the aged population [1]. The ﬁrst theory to
explain the cellular and molecular background of aging was
the Free Radical Theory of Aging (FRTA), proposed in the
1950’s [2], and has become one of the most studied theories.
The basic idea of this theory is that reactive oxygen species
and free radicals generated during physiological metabolism
and arising from reactions to exogenous factors initiate
degradation of biomolecules and the progressive accumula-
tion of these cellular damages ultimately results in aging
and age-related diseases. Because of increasing inconsistent
evidence, it is now accepted that this theory in its original
form or its variants cannot alone explain the aging process
[3, 4]. Nevertheless, FRTA cannot be rejected in its entirety,
since an impressive amount of data indicates that reactive
oxygen species- (ROS-) mediated aging phenotypes and
age-related disorders (aside from spontaneous errors in
signaling pathways and reactions of metabolites, e.g., reactive
aldehydes and sugars) [5–10] exist.
In normal metabolic cells, the production of reactive
oxygen and nitrogen species (ROS/RNS) from several
sources and their removal by antioxidant systems, including
endogenous or exogenous antioxidant molecules, are very
precisely balanced. Mitochondria play a major role in sup-
porting the redox balance, so maintaining the structural
and functional integrity of these organelles is essential for
normal cellular function. At physiological concentrations,
ROS/RNS are crucial in signaling processes. These ROS/RNS
are produced at very low levels, and the damage caused is
almost instantly repaired. The antioxidant enzymes within
the cells like catalase, superoxide dismutase (SOD), lactoper-
oxidases, and glutathione peroxidase inhibit the production
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of such free radicals and thus present a protecting eﬀect on
cells maintaining the balance.
Oxidative stress is deﬁned as an imbalance between
prooxidants and antioxidants, resulting in macromolecular
damage and disruption of redox signaling and cellular con-
trol [11]. Prooxidants are factors that help to generate ROS,
which in turn destroy cellular macromolecules, i.e., induce
protein oxidation, lipid peroxidation, and DNA damage
[12]. mtDNA due to its proximity to the site of ROS produc-
tion was thought to be intrinsically vulnerable [13]. By
contrast, antioxidants reduce oxidative stress, since they act
to counter or reduce the eﬀects of ROS [14].
Mitochondrial defects have been proposed to contribute
to the development of oxidative stress-related diseases
[15, 16]. Impaired mitochondrial function has been involved
in various human diseases; particularly, it is considered as the
main mediator of the aging process and subsequent age-
related diseases [17, 18]. If the reactions of free radicals and
other oxygen species contribute to accumulation of molecu-
lar damages giving rise to aging and age-related diseases,
antioxidants should prevent or slow down these processes
and prolong longevity. Based on this assumption, a huge
amount of studies were established and aimed at estimating
the eﬀect of the level of endogenous antioxidants and/or of
the administration of exogenous antioxidants on aging and
age-related processes and diseases.
The antioxidant’s positive eﬀects are veriﬁed by the
experimental biological observations which have found that
long-term administration of vitamin C decreased the iso-
prostane levels in rats [19]. Vitamin C was shown to decrease
the α-tocopheroxyl level in membranes or low-density
lipoprotein (LDL) and inhibits α-tocopheroxyl radical-
mediated propagation [20]. The protective eﬀect of vitamin
E against oxidative damage was also demonstrated. It is
explained by its direct action on a variety of oxygen radicals.
The mechanism of action of antioxidants seems to be wide-
spread: they might directly neutralize free radicals, they
quench iron which subsequently decrease ROS production,
and they decrease the concentration of peroxide and restore
oxidized membranes [21]. Antioxidants are considered as
a chemical to be able to induce antioxidant gene expres-
sion, to prevent LDL cholesterol from oxidation and pro-
vide the brain, the heart, and the liver with antiapoptotic
protection [22].
Carotenoids have gained special interest during the last
decades, due to their strong antioxidant, repairing, antiprolif-
erative, anti-inﬂammatory, and potential antiaging eﬀects.
They can be used to prevent oxidative stress-related diseases
and chronic inﬂammation. Astaxanthin is one of the most
powerful carotenoid on the market. In this review, special
focus is oriented towards these compounds.
2. The Mode of Action of Retinoids
Vitamin A (retinol) and its derivatives with or without bio-
logical activity, collectively referred to as retinoids, are crucial
for normal development and homeostasis of vertebrates. The
only source of retinoids is through diet (milk, liver, and eggs),
because these compounds cannot be synthesized de novo
[23]. Retinoids have long been appreciated as essential
factors for controlling the diﬀerentiation program of certain
epithelial cells and for their beneﬁc eﬀects on vision, growth,
reproduction, and resistance to infection [24]. The predomi-
nant natural retinoid in circulation is retinol that is trans-
ported at high concentrations (micromolar levels) via the
serum bound to retinol-binding protein (RBP), and from
there, it can be taken up by any cell for storage or potential
conversion into retinoic acid (RA). Once inside, the cell
retinol is converted into retinal via a reversible reaction cata-
lyzed by short-chain dehydrogenase/reductases (SDRs). In
this reaction, the ﬁrst step is the conversion to retinaldehyde
with the concomitant generation of NADH, and lastly, the
formation of retinoic acid by cytosolic aldehyde dehydroge-
nases (Figure 1). Retinoic acid can bind to and activate
nuclear hormone receptors (retinoic acid receptor (RAR)
and retinoid X receptor (RXR)). Three diﬀerent RXR isotypes
(RXR α, β, and γ) have been reported so far [25, 26]. RXRγ
has limited tissue expression including high levels in the
brain, anterior pituitary, and skeletal muscle [27].
Retinoic acid, the active metabolite of vitamin A, has
notable eﬀects on lipid and energy metabolism by modulat-
ing the phosphorylation state of AMPK and Akt [28] and
the rate of glucose uptake in L6 myotubes [29]. Treatment
of mice with all-trans retinoic acid (atRA) was described to
reduce body weight and adiposity independently of changes
in food intake, improved insulin sensitivity, and glucose
tolerance in lean and obese mice [30, 31] and was found to
promote skeletal muscle fatty acid oxidation [32] and irisin
production in skeletal muscles [32].
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Figure 1: The retinoid conversion cascade.
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SDRs are ubiquitary expressed and constitute a large
protein family involved in the reduction of a variety of sub-
strates. SRP-35 (Sarcoplasmic Reticulum Protein of 35 kDa)
was identiﬁed using a proteomic approach by Treves et al.
[33], and it belongs to the DHRS7C subfamily [34]. In muscle
cells, using retinol as its substrate, SRP-35 was proposed as a
target to aﬀect glucose metabolism in human patients with
metabolic disorders [35]. The biochemical characterization
of SRP-35 ﬁrmly support that it is a membrane-bound
protein with its catalytic site facing the cytoplasm; as a conse-
quence, both its products (retinaldehyde) and NAD(P)H are
released into the myoplasm. The generation of NADH in the
myoplasmmay possess functional signaling relevance; lactate
dehydrogenase requires NADH as reducing power to gener-
ate lactate from pyruvate, and NADH is available in the mito-
chondria where it is used to generate ATP. Nevertheless,
cytosolic NADH has been shown to regulate the activity of
the RyRs, especially in the heart [36, 37].
3. Astaxanthin: A Special Carotenoid
Carotenoids, the precursors of vitamin A, are natural pig-
ments supplied with regular highly conjugated π-bond sys-
tems, providing the natural yellow, orange, or red colors of
many vegetables and fruits [38]. Since the structural elucida-
tion of β-carotene by the two scientists Kuhn and Karrer in
1930, more than 750 naturally occurring carotenoids have
been reported to date [39]. Based on their structure, caroten-
oids can be compiled into two main groups: (i) the carotenes,
also called carotenoid hydrocarbons, which only contain
carbon and hydrogen and (ii) the xanthophylls or oxygen-
ated carotenoids that may contain diﬀerent functional
groups (epoxy, methoxy, hydroxy, carbonyl, and carboxyl
acid groups) [40, 41].
Besides the most notable carotenoid, β-carotene, another
carotenoid has been receiving great attention lately: astax-
anthin, a marine xanthophyll carotenoid ﬁrst isolated from
a lobster by Kuhn and Soerensen [42]. Astaxanthin is exten-
sively produced by algal species such as Haematococcus
pluvialis (where it accumulates up to 3.8% on the dry weight
basis), Chlorella zoﬁngiensis, and Chlorococcum and also by
the yeast Phaﬃa rhodozyma [43, 44]. Astaxanthin confers
the rich pink color observed in various aquatic species
including the salmonids and crustaceans and even some non-
aquatic species such as the ﬂamingo. Sea creatures cannot
produce astaxanthin themselves and must obtain it from
their diets, which include zooplankton and krill. Krill oil con-
tains appreciable content of astaxanthin at 0.1 to 1.5mg/mL
depending on processing methods [45]. Krill oil is a superior
source of EPA (eicosapentaenoic acid) and DHA (docosa-
hexaenoic acid) which are both long-chain omega-3 fatty
acids because the polyunsaturated fats are packaged as
phospholipids, which ultimately can be used instantly by
our body.
Astaxanthin is a fat-soluble nutrient (it incorporates into
cell membranes) with increased absorption when consumed
with omega-3-rich seed oil; however, it cannot be converted
to vitamin A and therefore cannot support retinol-speciﬁc
processes such as vision. With its unique molecular structure
[46], astaxanthin stretches through the bilayer membrane,
providing resilient protection against oxidative stress. It can
scavenge and quench ROS and free radicals (superoxide
anion, hydrogen peroxide, singlet oxygen, etc.) in both the
inner and outer layers of the cellular membrane [46] unlike
most antioxidants, which work either in the inner (e.g.,
vitamin E and β-carotene) or the outer side of the membrane
(e.g., vitamin C). Astaxanthin derived from the microalgae
H. pluvialis has been approved as a color additive agent in
salmon feeds and as a dietary supplement for human con-
sumption for more than 20 years in dosages up to 12mg
per day and up to 24mg per day for no more than 30 days
in Europe, Japan, and USA [47].
Recent human studies elaborate on the safety perspec-
tives of natural astaxanthin, and so far, no documented
negative eﬀects have been found over its 20 years of con-
sumption as a dietary [48]. Clinical studies have found that
natural astaxanthin supplementation improved blood ﬂow
in humans [49] and enhanced blood rheology by increasing
the ﬂexibility of erythrocyte membranes [50].
Astaxanthin emerged in the spotlight because of its
potential pharmacological eﬀects, including anticancer
[44, 51, 52], antidiabetic [53, 54], anti-inﬂammatory [55],
immune-stimulating eﬀects [44, 52], and antioxidant activ-
ities [55–59] as well as neuro-, cardiovascular, ocular-, and
skin-protective eﬀects [60–64]. Studies found that astax-
anthin reduces the oxidative stress caused by hyperglycemia
in pancreatic β-cells and improves glucose and serum insulin
levels in diabetes [65]. Furthermore, it has been suggested
that astaxanthin is a potential therapeutic agent against
atherosclerotic cardiovascular disease [66]. In an elegant
work, Barros et al. showed that “astaxanthin can directly
cross the blood-brain barrier to reach diﬀerent mammalian
brain regions” [64, 67, 68]. Here, we summarize the eﬀects
of astaxanthin on metabolism, insulin resistance, and type-
2 diabetes mellitus; furthermore, its advantages on muscle
performance, recovery, and atrophy, and eﬀects in the central
nervous system and the skin will also be discussed.
4. The Metabolic Effects of Astaxanthin
4.1. Insulin-Mediated Glucose Uptake. Skeletal muscle
accounts for 30-40% of body mass. As the major metabolic
tissue of the body, it plays an important role in the whole-
body metabolism and homeostasis. In the postprandial state,
skeletal muscle tissue is responsible for over 80% of insulin-
induced glucose uptake. The molecular mechanisms of
insulin-mediated glucose transport are intensively studied.
GLUT4 (glucose transporter type 4) is a glucose transporter
responsible for glucose uptake into adipocytes and muscle
tissue. The GLUT4 vesicles are mainly found perinuclearly
at a basal state which are translocated to the plasma mem-
brane by insulin-regulated vesicular traﬃc leading to glucose
transport into the cells and a simultaneous decrease of blood
glucose. Importantly, in case of insulin resistance and type-2
diabetes mellitus, the amount of GLUT4 is decreased [69]
and its translocation is impaired [70]. The insulin receptor
signaling involves the insulin receptor substrate- (IRS-) 1-
mediated activation of PI3K (phosphatidylinositol-3-kinase),
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resulting in Akt2 activation, inhibition of the Akt2 substrate
AS160 (Akt substrate 160, a GTPase-activating protein for
Rabs), and consequently, the activation of Rab8a and Rab14
GTPases in muscle cells [71]. The PI3K can also activate
the Rho-family GTPase Rac1 that is involved in the remodel-
ing of a cortical actin network by regulating the Arp2/3
complex and coﬁlin inﬂuencing GLUT4 translocation [72].
The joint activation of the PI3K-mediated Akt2/AS160 and
Rac1 signaling pathways is necessary for the translocation
of GLUT4 (Figure 2).
4.2. Oxidative Stress and Insulin Resistance. Insulin resistance
is a deﬁnition for insuﬃcient response of tissues to the eﬀect
of insulin, resulting decreased insulin-mediated glucose
uptake into the skeletal muscle, increased hepatic glucose
production in the liver, and impaired suppression of lipolysis
in adipose tissue. The development of insulin resistance is an
intensively studied, complex, and not fully known process.
Numerous papers have reported that the mitochondrial
dysfunction is linked to insulin resistance and type-2 diabetes
mellitus [73–75]; however, it remains unclear whether
perturbations in mitochondrial functional capacity are
causes, consequences, or key contributors to insulin resis-
tance [74, 76]. Mitochondria are the major sources of reactive
oxygen species. Insulin resistance is characterized by ineﬃ-
cient mitochondrial coupling, low level of ATP, and the
formation of excess amount of ROS despite the normal to
high oxygen consumption [73, 75]. Mitochondrial dysfunc-
tion was ﬁrst described in glucose intolerance in 1975 [77].
Several studies suggested that the loss in mitochondrial
content and/or function and consequently the decreased
mitochondrial oxidative capacity lead to insuﬃcient lipid
oxidation, accumulation of lipid excess resulting in the
development of insulin resistance [74]. The accumulation
of ROS can activate various kinases such as PKCs (protein
kinases C), IKK β (inhibitor κB kinase-β), JNK (c-Jun N-
terminal kinase), and p38 MAPK (mitogen-activated protein
kinase), which induce the phosphorylation of serine residues
in IRS-1 leading to the inhibition of its activity and directing
it to proteasomal degradation [74, 78–81]. JNK1 has a crucial
role in the development of insulin resistance by inhibiting
IRS activity via phosphorylation of Ser307 residue preventing
its interaction with the insulin receptor [82, 83]. Further-
more, oxidative stress inhibits the retromer function in a
casein kinase-2- (CK2-) dependent manner leading to the
sorting of GLUT4 vesicles to lysosomes for degradation
[84] (Figure 2).
4.3. Astaxanthin Treatment, Insulin Sensitivity, and Muscle
Metabolism. Astaxanthin accumulated in skeletal muscle
and was shown to reduce hyperglycemia and ameliorate
insulin secretion and sensitivity by improvement of glucose
metabolism and β-cell dysfunction by GLUT4 regulation.
Astaxanthin administration increased the translocation of
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Figure 2: Astaxanthin improves insulin sensitivity and glucose uptake. Schematic representation of the insulin-mediated signaling pathway
resulting in the translocation of GLUT4 glucose transporter and glucose uptake. The oxidative stress can lead to insulin resistance by
activating various kinases such as JNK, which catalyze the phosphorylation of serine residues in IRS-1 inhibiting its activity and
preventing its interaction with the insulin receptor. Furthermore, oxidative stress switches the GLUT4 sorting to the degradation of
GLUT4 vesicles. The dietary astaxanthin administration improves insulin sensitivity, IRS-1 activation, Akt phosphorylation, and GLUT4
translocation in skeletal muscle leading to increased insulin sensitivity and a decrease in blood glucose level.
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GLUT4 transporter and also insulin-dependent glucose
uptake in line with increased phosphorylation of IRS-1
tyrosine and Akt and a decrease in JNK and IRS-1 Ser307
phosphorylation in L6 muscle cells [85]. Inﬂammatory cyto-
kines (e.g., TNFα, tumor necrosis factor α) and fatty acids are
released from adipose tissue and serve as the major con-
tributors to induce insulin resistance [85, 86]. Palmitate
generate ceramide which triggers mitochondrial oxidative
stress and insulin resistance [87], and the role of TNFα
in the generation of insulin resistance was also shown
[86]. Importantly, astaxanthin treatment restored TNFα-
and palmitate-induced insulin resistance and decreased
ROS generation of L6 muscle cells [85].
Astaxanthin treatment (8mg/day, 8 weeks) was eﬀective
in patients with type-2 diabetes mellitus: reduced visceral
fat mass, serum triglyceride, very-low-density lipoprotein
cholesterol concentration, and decreased systolic blood
pressure. Furthermore, astaxanthin signiﬁcantly reduced
the fructosamine and plasma glucose concentration [54]. In
a metabolic syndrome model SHR/NDmcr-cp (cp/cp) rats
where spontaneous hypertension, obesity, hyperinsulinemia,
and mild hyperlipidemia evolved, the astaxanthin treatment
(22 weeks) ameliorated features of metabolic syndrome:
improved insulin resistance; decreased fasting blood glucose,
homeostasis of insulin resistance (HOMA-IR), triglyceride,
and fatty acid levels; and induced a signiﬁcant reduction of
arterial blood pressure and the size of fat cells in white adi-
pose tissue [88]. Astaxanthin ameliorated high-fat, choles-
terol and cholate diet-induced glucose intolerance and
reversed hepatic inﬂammation and ﬁbrosis in C57BL/6J mice
[89]. Moreover, astaxanthin administration in a type-2
diabetic db/db (leptin receptor mutated) mice improved the
intraperitoneal glucose tolerance test and protected pancre-
atic β-cells against glucose toxicity by reducing blood glucose
concentration and hyperglycemia-induced oxidative stress
[65]. Insulin resistance can also be detected in another
animal model (high fat and high fructose diet-fed mice),
where the astaxanthin treatment improved their insulin
sensitivity parameters [53]: lowered insulin and glucose
levels in the plasma, ameliorated insulin signaling, and
enhanced Akt phosphorylation and GLUT4 translocation
in skeletal muscle [53].
The number and function of mitochondria inﬂuence the
fatty acid utilization of the skeletal muscle. The peroxisome
proliferator-activated receptor-γ coactivator-1a (PGC-1α) is
a key transcriptional coactivator playing a role in the biogen-
esis of mitochondria in the muscle. PGC-1α was signiﬁcantly
elevated in skeletal muscle samples following astaxanthin
intake, and cytochrome C levels were also increased in mice
[90]. Moreover, the levels of plasma fatty acids were
decreased after exercise in the astaxanthin-fed mice [90],
and the fat utilization of skeletal muscle was improved during
exercise in a treadmill running model by activation of
carnitine palmitoyltransferase I [91]. Interestingly, PGC-1α
increases the level of GLUT4 and has multiple roles in the
pathogenesis of type-2 diabetes mellitus [92], but the eﬀects
of astaxanthin on the PGC-1α/GLUT4 pathway have not
been studied. It has also been demonstrated that peroxisome
proliferator-activated receptor (PPAR), which has a major
role in the carbohydrate metabolism, is a novel target for
astaxanthin. The antioxidant molecule can bind dose-
dependently to PPARγ and act as an antagonist or an agonist
depending on the cell context [93].
4.4. Protective Eﬀect of Astaxanthin on Diabetes Mellitus
Complications. Diabetes mellitus increases ROS production
and also decreases antioxidant defense capacity. Reactive
radicals are produced in several ways, one source is the
activated macrophages and neutrophils. Release of large
amounts of ROS leads to oxidative stress of all cell compo-
nents and induces chronic inﬂammatory responses [81, 94].
It has also been suggested that carotenoids are capable of pro-
tecting the diﬀerent tissues from the long-term consequences
of diabetes including nephropathy, infectious diseases, and
abnormalities in the neuronal system and eye. Several reports
try to examine and discuss the mechanisms behind the
biological eﬀects of carotenoids for the prevention of the
complications of diabetes mellitus.
Astaxanthin supplementation markedly reduced the level
of inﬂammation-related proteins COX-2 (cyclooxygenase-2),
iNOS (inducible nitric oxide synthase), MCP-1 (monocyte
chemoattractant protein 1), NF-β (nuclear factor beta) in
the liver, and the ROS-induced lipid peroxidation in
streptozotocin-induced diabetic rats [95]. In human mesan-
gial cells, astaxanthin prevented the high-glucose exposure-
induced elevated ROS production in the mitochondria, so it
can have a protective eﬀect against diabetic neuropathy
[96]. In human neutrophil cells, astaxanthin prevented the
high-glucose-induced ROS/RNS production and improved
the phagocytic capacity of the cells [97]. The redox balance
in the lymphocytes was ameliorated by astaxanthin applica-
tion via lowering the activities of catalase, restoring ratio
between glutathione peroxidase and glutathione reductase
activities and lowering the scores of lipid oxidation in an
alloxan-induced diabetic rat model [98]. Inﬂammation-
related neuronal apoptosis leads to learning and memory
deﬁcits. Astaxanthin decreased the activity of apoptosis-
related molecules (TNF, IL-1, and IL-6) and caspases 3 and
9 in the cortex and hippocampus of diabetic rats improving
cognitive deﬁcits [99]. High-glucose concentration-induced
superoxide, nitric oxide, and peroxynitrite generation was
also reduced by astaxanthin treatment in proximal tubular
epithelial cell, which inhibited the nuclear translocation of
NF-κB p65 subunit [100]. Oxidative stress is the major cause
of renal ﬁbrosis during the progression of diabetic nephrop-
athy. In diabetic (db/db) mice, astaxanthin administration
improved the development and acceleration of diabetic
nephropathy [101]; it improved experimental diabetes-
induced renal oxidative stress and prevented renal ﬁbrosis
by upregulating connexin43 and activating the antioxidant
Nrf2- (NF-E2-related factor 2-) ARE (antioxidant responsive
element) pathway in glomerular mesangial cells [102]. In
streptozotocin-induced diabetic rats, 12 weeks of astaxanthin
treatment ameliorated morphological changes in the kid-
ney via decreasing the protein expression of ﬁbronectin
and collagen IV and through the activation of Nrf2-ARE
signaling [103]. The therapeutic eﬀect of astaxanthin and
other carotenoids regarding long-term complications of
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diabetes mellitus has been demonstrated in a review of
Roohbakhsh et al. [104].
5. Effects of Astaxanthin on Muscle
Performance, Recovery, and Atrophy
5.1. Eﬀects of Antioxidants and Their Targets in Skeletal
Muscle Work. During skeletal muscle work, ROS are
generated from either mitochondrial or nonmitochondrial
sources. These include NADPH, xanthine oxidases, phos-
pholipase A2, and nitric oxide that originates from NO
synthase. During moderate exercise, oxidative balance is kept
within physiological limits to minimize the eﬀects of oxida-
tive damage [105]. It contains a complicated antioxidant
defense system: antioxidant enzymes like glutathione perox-
idases, superoxide dismutase (SOD), thioredoxins, peroxire-
doxins, and catalase. They are capable of reducing ROS,
while endogenous antioxidant substrates such as glutathione
can scavenge ROS/RNS [105]. Physical exercise per se has
antioxidant eﬀects by enhancing these endogenous antioxi-
dant defenses [106], and in pathological conditions, like
diabetes or cancer, this endogenous antioxidant eﬀect is
probably the most eﬃcient health-promoting mechanism.
Despite this, antioxidant treatment is very popular and
widely used in medical treatment and also among individuals
doing recreational or professional sports to enhance activity.
These treatments can modify skeletal muscle signaling like
force production, glucose uptake, insulin sensitivity, ion
pump functions, and mitochondrial biogenesis [105]. How-
ever, the frequently supplemented antioxidants are usually
vitamin C and E which generalized nontarget scavengers
of all ROS. This leads to the fact that in some cases, these
antioxidant supplementations does not decrease, or may
even increase, the incidence of human diseases [107]
explaining the urgent need of new, more speciﬁcally working
antioxidant compounds.
Mitochondria have an essential role in skeletal muscle
contraction. This is the place of ATP synthesis, modulates
redox status, controls pH, and contributes in physiological
calcium ho-homeostasis. Since without ATP and calcium
muscle ﬁbers do not contract, any alteration on mitochon-
drial status could lead to myopathy or muscle-related disease
like diabetes. It was shown that chronic exercise increased
mitochondrial size and density and its cardiolipin content
in type-2 diabetes [108]. In Barth syndrome, which is an
X-linked recessive disorder manifesting in muscle weakness
and cardiomyopathy, dysfunction of tafazzin (a mitochon-
drial acyltransferase) reduces cardiolipin content and alters
mitochondrial function. Treatment with mito-Tempo (a
mitochondria-speciﬁc antioxidant) in cardiac myocytes lack-
ing tafazzin normalized its level, decreased mitochondrial
ROS production, and increased cellular ATP content [109].
Unfortunately, not all the mitochondrial-targeted treatment
have beneﬁcial eﬀects. Recent study shows in Barth Syn-
drome again that a targeted overexpression of catalase in
mitochondria did not prevent the development of myopathy
in mice [110]. Next to the pathological conditions, aging
also decreases mitochondrial functions. In a special animal
model of aging, mtDNA mutator mice (they accumulate
errors in their mitochondrial DNA and present subse-
quent changes in the respiratory chain composition)
were treated with the antioxidant SkQ1 (10-(6′-plastoqui-
nonyl)decyltri-phenylphosphonium cation) and the phos-
phorylation capacity of mitochondria in skeletal muscle
was improved [111]. This positive eﬀect of SkQ1 was
partly because the treatment restored the cardiolipin
amount in the mtDNA mutator mice to a wild-type
level.
5.2. Eﬀects of Astaxanthin during Physical Exercise and
Muscle Injury. During heavy exercise, training and competi-
tion elevation of reactive oxygen and nitrogen species evolve
causing damage in lipid, protein, and nucleic acid molecules.
That is why, special nutritional strategy, like supplementa-
tion with antioxidant compounds, is now essential for
active individuals and athletes. Based upon mouse exercise
experiments, supplementation with astaxanthin can eﬀec-
tively improve the side eﬀects of exercise metabolism and
the individual’s performance and recovery.
Four weeks of astaxanthin treatment in mice prolonged
the running to exhaustion. During exercise, astaxanthin
administration facilitated lipid metabolism instead of glucose
utilization, which improved the endurance and reduced
adipose tissue [91]. The same group showed the eﬀect of
astaxanthin on ROS-targeted proteins involved in skeletal
muscle metabolism during exercise. They found that the
oxidative stress-induced modiﬁcation of lipid peroxidase
carnitine palmitoyltransferase I (CPT I) was reduced with
the application of antioxidant astaxanthin [112]. Liu and
coworkers [90] also suggested that astaxanthin intake
increases the PGC-1α level in skeletal muscle leading to the
acceleration of lipid utilization by the activation of mitochon-
drial aerobic metabolism during exercise. In oxidative-type
soleus muscle, 45 days of astaxanthin supplementation
resulted mitochondrial-targeted action, as the treatment
increased glutathione content in the mitochondria during
exercise, limited oxidative stress, and delayed exhaustion in
Wistar rats [113].
Unlike in exercising mouse model, where astaxanthin
supplementation enhanced mainly the utilization of fat and
depleted muscle glycogen stores during endurance exercise
[114], 4 weeks of treatment did not inﬂuence signiﬁcantly
the carbohydrate and fat oxidation rate in exercising humans
[115]. In this study, Res et al. also reported that there is
no signiﬁcant eﬀect of astaxanthin supplementation on
performance during endurance training not even on lon-
ger training time periods or in a higher dose (20mg/day,
4 weeks) in young, trained individuals [115]. Moreover, a
high carotene-containing diet also proved to be eﬀective to
moderate some of the negative outcomes of sarcopenia on a
low physical performance by reducing DNA damage in aged
humans [116]. It has been proved that astaxanthin-
containing diet modiﬁed the expression level of PGC-1α,
thereby inducing the mitochondrial biogenesis in vivo [90].
It was shown also that the prolonged supplementation has
not modiﬁed the lipid oxidation in order to spare glycogen
stores during training, as it already proved in animal studies,
which can be due to the increased ﬁtness levels of the
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inspected subjects [91]. Krill oil treatment also activated the
mTORC1 signaling pathway as it was shown in C2C12 myo-
blasts; however, in young, untrained, healthy individuals, 3 g
of krill oil (0.5 g astaxanthin content) administration during
8 weeks did not elevate signiﬁcantly the muscle force in
resistance exercise [117]. In elder subjects (between 65 and
85 years), astaxanthin-containing (12mg) diet with addi-
tional antioxidative properties (10mg tocotrienol, 6mg zinc)
signiﬁcantly improved the performance in endurance train-
ing and additionally enhanced the force and muscle mass
compared to the control group with placebo and training
alone [118]. However, authors did not provide information
about which signaling pathways were involved and there
was also a lack of data about the chronic eﬀects of the astax-
anthin treatment.
A fresh study showed that astaxanthin treatment helps to
preserve mitochondrial integrity and function in heat-
induced skeletal muscle injury examined in cultured C2C12
cells and isolated rat skeletal muscle ﬁbers. The supplementa-
tion prevented mitochondrial fragmentation and depolariza-
tion, reduced apoptotic cell death, and increased PGC-1α and
mitochondrial transcription factor A expression following
heat stress [119]. Human investigations have also been
carried out to show the eﬀect of astaxanthin application
on exercise-induced muscle injury. Eccentric loading was
applied for 3 weeks in resistance-trained men, and diﬀerent
markers of muscle injury (muscle soreness, creatine kinase
level, and muscle performance) were tested. According to
the results, the antioxidant supplementation did not
favorably aﬀect the aforementioned markers [120]. In
another study, cardiac troponin release was examined after
endurance-type exercise in cyclists. In this experiment, astax-
anthin treatment had no eﬀect on antioxidant capacity (uric
acid, malondialdehyde) and inﬂammation (high-sensitivity
C-reactive protein) markers and did not change creatine
kinase release induced by exercise [121]. However, a positive
eﬀect of antioxidant astaxanthin was suggested in untrained
healthy men, where the supplementation signiﬁcantly
increased carbohydrate oxidation and oxygen consumption
during exercise and decreased the plasma insulin level. These
results indicate that astaxanthin-rich foods can positively
aﬀect aerobic metabolism of carbohydrate and fat during rest
and exercise [122].
However, several studies using a variety of animal model
of myocardial ischemia and reperfusion demonstrated eﬃ-
ciency of astaxanthin supplementation by reducing markers
of oxidative stress and inﬂammation [123]; one has to
consider several aspects with regard the use of antioxidant
nutritional supplementation for attenuating muscle injury.
These supplements seem to attenuate a certain sign of
muscle injury during exercise; however, it is not clear what
is the optimal dose and treatment period and whether the
eﬀectiveness is speciﬁc to nonresistance-trained individuals
[124]. It is also urgent to ﬁnd the best markers of skeletal
muscle injury and more suitable analytical methods so that
more reliable conclusion can be generated regarding the
eﬀect of antioxidant agents like astaxanthin in exercise-
induced muscle damage. All the questioned aspects of
astaxanthin supplementation on exercise performance and
recovery have been collected and discussed in a recent
review [125].
5.3. Muscle Atrophy Is Ameliorated by Astaxanthin
Treatment. Skeletal muscle atrophy can occur in case of
physiological and several pathological conditions such as
immobilization, aging, chronic diseases (e.g., heart failure
and renal failure), or cancer. A correlation between oxidative
stress and muscle mass has already been observed, the
increased production of reactive oxygen species has impor-
tant roles in disuse muscle atrophy by increasing protease
activation [126, 127], and the activation of oxidative stress
pathways in atrophying muscles has been suggested to cause
apoptosis. Oxidative stress participates in the activation of
lysosomal proteases (e.g., cathepsin L), calcium-activated
proteases (calpain), and also the ubiquitin-proteasome path-
way during disuse muscle atrophy leading to the activation of
proteolysis [126–128]. The eﬀects of antioxidants in disuse
muscular atrophy have been investigated [129], and the
antioxidant astaxanthin comes to the front as an eﬀective
molecule to prevent inactivity-induced muscle atrophy.
Astaxanthin supplementation prior and/or during hind limb
unloading prevented muscle atrophy in diﬀerent animal
models. Dietary astaxanthin intake for 14 days before and
during hind limb immobilization attenuated muscle atrophy
in rats and interfere with the increased expression of CuZn-
SOD (CuZn-superoxide dismutase), cathepsin L, calpain,
and ubiquitin caused by immobilization [130]. In another
rat model, the dietary astaxanthin supplementation for 2
weeks prior to unloading and during 7-day long immobiliza-
tion attenuated soleus muscle atrophy and suppressed
myonuclear apoptosis measured by the number of TUNEL-
positive nuclei [131]. The capillary number is related to the
loading and activity of skeletal muscle [132]; the unloading
results in capillary regression. Administration of astaxanthin
decreased the ROS production, decreased the level of
SOD-1, and increased the expression of VEGF (vascular
endothelial growth factor) in the soleus of hind limb
unloaded rats [133, 134]; furthermore, the 7-day long
astaxanthin administration reduced the capillary regression
during unloading [133], while the 2-week long treatment
maintained the capillary network near control levels
[134]. Interestingly, the 2-week astaxanthin diet had a little
eﬀect on soleus muscle mass during unloading; other mus-
cles were not examined in this study [134]. Further study
showed that the combinatory treatment with dietary astax-
anthin supplementation and heat stress prevented disuse
muscle atrophy in the soleus muscle, and this protective
eﬀect may be partially due to the higher number of satel-
lite cells (stem cells of the skeletal muscle) [135]. Increased
ROS production within immobilization-induced skeletal
muscle mediates TGF-β1-induced ﬁbrosis via promoting
the diﬀerentiation of ﬁbroblasts and increasing collagen
synthesis, where astaxanthin application attenuated skeletal
muscle ﬁbrosis [136]. Based on a recent paper by Liu
et al., astaxanthin formulation in combination with a
functional training program increased the tibialis anterior
muscle size determined from magnetic resonance imaging
in the elderly [118].
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6. Effects of Astaxanthin in the Central Nervous
System and the Skin
Oxidative stress is thought to be involved in the pathogenesis
and progression of age-related cognitive impairments [137]
as well. The high lipid content and metabolic rate make
the neuronal system particularly vulnerable to oxidative
stress. Mitochondrial damage and dysfunction due to oxi-
dative stress are reﬂected in age-related neurodegenerative
diseases such as Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, and amyotrophic lateral sclerosis
[138]. In addition to metabolic failure, the membrane of
the damaged mitochondria is impaired, their membrane
potentials are lost, and they become permeable resulting
in the release of cytochrome c. These processes lead to
the activation of caspases that induce apoptosis of neuro-
nal cells.
Dietary supplementation with antioxidant vitamins has
shown preventive action against oxidative stress and pro-
tected or even reversed the age-related changes in antioxi-
dant activity in the central nervous system [139]. In a
recent review, Vina and colleagues [140] demonstrated that
the systemic oxidative stress and the cognitive function in
Alzheimer’s disease patients are inversely proportional. The
administration of antioxidants, such as vitamin C or E, has
been shown to be eﬀective in reducing the symptoms of oxi-
dative stress and cognitive loss [141]. Astaxanthin has
recently gained a lot of interest, because among its variety
of health-promoting eﬀects mainly through the modulation
of parameters related to oxidative stress but also to inﬂam-
mation, it is able to penetrate the blood-brain barrier accu-
mulating in the brain and has evidenced positive eﬀects on
neurodegeneration as well. The neuroprotective eﬀect of
astaxanthin was also published using in vitro and in vivo
models. The 1-methyl-4-phenylpyridinium (MPP+) toxin
was examined which induces neuronal cytotoxicity. The
oxidative stress evoked by this neurotoxin opens the
mitochondrial permeability transition pore and subsequently
triggers the release of cytochrome c. Astaxanthin increases
the activity of SOD and catalase, leading to the inhibition of
MPP+-induced ROS generation [142]. Astaxanthin seems
to restore brain-derived neurotrophic factor (BDNF) levels
in both the brains and the hippocampus in rats, thereby slow-
ing brain aging [143]. Astaxanthin’s antineurotoxic eﬀect was
also demonstrated in an in vivo mouse model of Parkinson’s
disease [144]. A recent review summarizes further infor-
mation on the potential neuroprotective role of astax-
anthin [145].
Age-related changes of the skin are thought to be driven
by two basic mechanisms: biological aging and exposure to
ultraviolet rays (photoaging). Photoaging leads to the degra-
dation of components of the extracellular matrix (collagen,
elastin), resulting in wrinkles, pigmentation, and deteriora-
tion of the skin texture [146]. UV light initiates production
of ROS in the skin. Oxidation of C8 guanine base by ROS,
8-hydroxy-2deoxyguanosine (8-OHdG) is produced, which
is a marker of DNA damage [147]. In keratinocytes and
ﬁbroblasts, ROS activate cytokine receptors and growth fac-
tors that will induce the mitogen-activated protein kinase
(MAP kinase) and subsequently activate transcription factors
of activator protein-1 (AP-1) [148]. AP-1 potentiates the
expression of the matrix degrading enzymes, the matrix
metalloproteinases (MMPs), which impair collagen in the
skin [146]. Continuous carotenoid administration demon-
strated protection against UV light [149], and in particular,
astaxanthin supplementation had a positive impact on aging
skin status, the skin elasticity was restored, the wrinkle
formation was attenuated, and epidermal barrier integrity
was preserved [150–153]. A comprehensive review of
Davinelli et al. summarizes the role of astaxanthin in skin
physiology [154].
7. Conclusions
To summarize, the antioxidant astaxanthin has attracted
increasing attention as an eﬀective molecule to prevent oxi-
dative stress-mediated and age-related diseases. Astax-
anthin has been reported to lower plasma glucose and
insulin levels and to improve whole body insulin sensitivity
and insulin-stimulated glucose uptake. Based on the
reviewed studies, it can act as an insulin sensitizer. Astax-
anthin also improved disuse muscle atrophy, and it has a
neuroprotective role and can prevent the photoaging of
the skin. Several papers showed that the excess amount of
ROS is involved in the development and progression of
chronic diseases, including the pathogenesis of insulin resis-
tance and type-2 diabetes. Pinpointing the further details of
the antioxidant astaxanthin eﬀect can yield translational
beneﬁts for people with metabolic disease. However, results
of studies on the supplementation of model organisms with
antioxidants, vitamins, and other antioxidants are diver-
gent; many studies show no eﬀect or even negative life-
prolonging eﬀect. Despite these contradictory conclusions,
the beneﬁcial eﬀects of antioxidants are undoubted in
pathological cases (e.g., antioxidant deﬁciency); additional
studies are needed to demonstrate a positive correlation
between antioxidant administration and longevity/or slow-
ing aging for healthy people.
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